Open Consultations
-
International Day of People with Disability 2025 Survey
We’re seeking your feedback on the International Day of People with Disability (IDPwD) 2025 program. Your input will help shape IDPwD in 2026.
Closes 9 February 2026
-
Have your say about the MRFF Research Mission program
We are seeking your views on the Medical Research Future Fund (MRFF) Research Missions program. The Medical Research Future Fund (MRFF) is a $24.8 billion long-term investment supporting Australian health and medical research. The Research Missions program is one of the...
Closes 27 February 2026
-
Modernising gap-only billing – replacing Medicare cheques with electronic benefit payments
Modernising gap-only billing – replacing Medicare cheques with electronic benefit payments In the 2025-26 Mid-Year Economic and Fiscal Outlook the Australian Government announced that government cheques will cease by 1 July 2028, including Medicare benefit cheque payments under Pay...
Closes 27 February 2026
-
Getting it Right: A New Definition for NDIS Providers
Share your thoughts on the Getting It Right: A New Definition for NDIS Providers consultation In December 2023, the Independent Review of the National Disability Insurance Scheme (NDIS Review) recommended the Australian Government “develop and deliver a risk-proportionate model for the...
Closes 28 February 2026
-
Proposed Amendments to the Gene Technology Regulations 2001
We would like to thank all the stakeholders that took part in public consultation on the proposed amendments to the Gene Technology Act 2000 (GT Act) that occurred in late 2024. Amendments to the Gene Technology Regulations 2001 (GT Regulations) are the next step in...
Closes 1 March 2026
Closed Consultations
-
Weekly Bed Availability Request - 23 January 2026
Please complete the data survey by close of business today. Please do not use any other means to provide your data, as this impacts our consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by close of business Tuesday 27 January...
Closed 27 January 2026
-
Review of the National Rural Health Commissioner Legislative Framework
Almost 30% of Australians live in rural and remote areas, where research consistently shows poorer health outcomes compared to urban populations. These disparities include higher rates of illness and mortality, which worsen with increasing remoteness ( AIHW ). The National Rural...
Closed 25 January 2026
-
NDIS Evidence Advisory Committee Consultation December 2025
The NDIS Evidence Advisory Committee (EAC) was established in an ongoing capacity by the Australian Government in response to the NDIS Review . The EAC will make recommendations to government on the safety, suitability and value for money of supports for NDIS funding , drawing on the best...
Closed 20 January 2026
-
Weekly Bed Availability Request - 16 January 2026
Please complete the data survey by close of business today. Please do not use any other means to provide your data, as this impacts our consolidation and analysis. This information will be submitted to the Tasmanian Health Service (THS) by close of business Tuesday 20 January...
Closed 20 January 2026
-
DIR 221 - Clinical trial of a genetically modified Escherichia coli for the treatment of ulcerative colitis
The Gene Technology Regulator has received a licence application (DIR 221) from Melius MicroBiomics Pty Ltd for a clinical trial of a genetically modified (GM ) Escherichia coli for the treatment of ulcerative colitis. Comments are now being sought on the consultation version of the...
Closed 14 January 2026
We Asked, You Said, We Did
Here are some of the issues we have consulted on and their outcomes. See all outcomes
We asked
Between 28 October 2025 and 10 November 2025, we sought feedback on proposed improvements to the Health Insurance (Bonded Medical Program) Rule 2020.
You said
We heard from over 300 current and former legacy and statutory Program participants, universities and professional bodies who provided feedback on the proposed changes.
We heard support for:
- Removal of the ‘fellowship’ requirement, enabling all participants to commence and complete their Return of Service Obligation (RoSO) earlier in their career.
- Increased flexibility for former Bonded Medical Places Scheme participants with a 52 week RoSO by allowing pro-rata part time RoSO.
- Minimising evidence administration to reduce the administrative burden for participants.
- Altering telehealth eligibility to the location of the provider only.
We heard concerns about changes:
- To location eligibility impacting participants’ ability to return service.
- Being applied inconsistently to legacy and statutory Program participants.
- Adding to existing administration and communication challenges.
We did
Feedback from this survey shaped the advice provided to the Minister. Should changes be made to the Rule, they will commence the day after they are registered on the Federal Register of Legislation. We will keep participants informed about implementation progress.
Thank you to everyone who participated in this consultation.
We asked
Between 8 September and 3 November 2025, we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for licence application DIR 218 for the commercial release of a genetically modified (GM) tomato from All Aussie Avocados Pty Ltd, trading as All Aussie Farmers.
You said
During the 8-week consultation period, we received advice from prescribed Government agencies, the Gene Technology Technical Advisory Committee, and the public.
We heard support for:
- the overall conclusions of the RARMP
- the licence conditions for DIR 218
We also heard concerns for:
- the potential negative impacts on people and the environment
- the potential for horizontal gene transfer of the antibiotic resistance gene
- the potential for increased weediness as a result of the introduced genes.
We did
We analysed the feedback provided during the public consultation process in finalising the RARMP. The issues raised and how they were addressed can be found in Appendices B and C of the final RARMP.
The Gene Technology Regulator issued a licence to All Aussie Avocados Pty Ltd for the commercial release of a GM tomato on 6 January 2026. More details, including the final version of the RARMP and the licence, are available at DIR 218 | Office of the Gene Technology Regulator.
We appreciate all those who provided input to the consultation – your feedback will help to ensure that any risks posed by gene technology to people and the environment continue to be managed.
We asked
Between 24 July and 18 September 2025, we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for the DIR 217 licence application (Commercial supply of genetically modified therapeutic from Ferring Pharmaceuticals Pty Ltd).
You said
During the 8-week consultation period, we received advice from prescribed Government agencies, the Gene Technology Technical Advisory Committee, and the public.
We heard support for:
- the thoroughness of the RARMP
- the overall conclusions of the RARMP
- the inclusion of post-release review in the draft licence conditions.
Some submissions sought clarification on prevalence and serotyping of human adenoviruses in Australia.
We did
We analysed the feedback provided during the public consultation process in finalising the RARMP. The issues raised and how they were addressed can be found in Appendices B and C of the final RARMP.
The Gene Technology Regulator issued a licence to Ferring Pharmaceuticals Pty Ltd for the commercial supply on 17 October 2025. More details, including the final version of the RARMP and the licence, are available at DIR 217 | Office of the Gene Technology Regulator.
We appreciate all those who provided input to the consultation – your feedback will help to ensure that any risks posed by gene technology to people and the environment continue to be managed.